pharma · Brain Metastasis from Estrogen Receptor Positive, HER-2 Negative Breast Cancer · Acute Myeloid Leukemia
Stemline Therapeutics (United
Stemline Therapeutics B.V.
Stemline Therapeutics (United trial registry — 7 ClinicalTrials.gov studies with program phase, status, and indication context.
New York, USA HQ
767 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- New York, USA
- Employees
- 767
- Programs
- 7
- Drugs
- 29
- Patents
- 0
Stemline Therapeutics (United clinical trials
Registry index of 7 ClinicalTrials.gov studies linked to Stemline Therapeutics (United programs — each row shows trial ID, program name, phase, status, and indication.
Stemline Therapeutics (United trial registry — 7 ClinicalTrials.gov studies with program phase, status, and indication context.
Recent trial activity
Latest clinical program signals indexed for Stemline Therapeutics (United.
Trial registry
-
CTIS ↗ - 2024-512878-98-00CTIS ↗
ELA-0121
Brain Metastasis from Estrogen Receptor Positive, HER-2 Negative Breast Cancer
- 2024-512926-27-00CTIS ↗
MEDOPP545
patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative, ESR1-mutated, advanced breast cancer progressing to endocrine therapy and CDK4/6 inhibitors.
-
CTIS ↗ - 2024-515445-42-00CTIS ↗
STML-ELA-0422
Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence
-
CTIS ↗ -
CT.gov ↗